OTC Markets · Biotechnology · USD
Lyra Therapeutics, Inc. (LYRA) Stock Analysis
Lyra Therapeutics, Inc. (LYRA) is a Biotechnology stock listed on OTC Markets and quoted in US Dollar.
Last Updated: October 20, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
LYRA Key Statistics
As of Oct 20, 2026Trading
- Open
- $0.19
- Previous Close
- $0.19
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.50
Valuation
- Market Cap
- $337.23K
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 0.85
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −18.62
Financials (FY)
- Revenue (FY)
- $398.00K−74.05%
- Net Income (FY)
- −$28.92M
- Shares Outstanding
- 1.77M
- 1-Year Return
- −97.21%
Dividend and dates
- Avg Volume
- 790.00
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 20, 2026, LYRA closed at $0.19, −97.21% over 1 year.
Lyra Therapeutics, Inc. (LYRA) has a market capitalization of $337.23K.
In fiscal 2025, LYRA reported revenue of $398.00K.
LYRA Stock Return by Calendar Year
Lyra Therapeutics, Inc. (LYRA) return since May 2020: what $10,000 became
- 1 year
- $10,000 $279
- −97.21%
- 5 years
- $10,000 $5
- −99.95%
- Since May 2020
- $10,000 $2
- −99.98%
If you had invested $10,000 in Lyra Therapeutics, Inc. (LYRA) at the close on May 1, 2020, the earliest close on record here, it would have been worth $2 at the close on October 20, 2026: −99.98% in total, −73.10% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −93.83% |
| 2025 | −70.16% |
| 2024 | −96.06% |
| 2023 | +66.88% |
| 2022 | −27.98% |
| 2021 | −61.75% |
| 2020 (partial year) | −38.58% |
As of October 20, 2026.
LYRA Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $398.00K | −$28.92M | −7,266.1% |
| 2024 | $1.53M | −$93.44M | −6,090.9% |
| 2023 | $1.56M | −$62.68M | −4,023.1% |
| 2022 | $1.36M | −$55.28M | −4,055.6% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $398.00K | — | −$29.55M | −$28.92M | −7,266.1% |
| 2024 | $1.53M | — | −$60.73M | −$93.44M | −6,090.9% |
| 2023 | $1.56M | — | −$65.53M | −$62.68M | −4,023.1% |
| 2022 | $1.36M | — | −$54.99M | −$55.28M | −4,055.6% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
LYRA Valuation vs Biotechnology Median
Median of 608 stocks| Metric | LYRA | Biotechnology median | vs median |
|---|---|---|---|
| P/S ratio | 0.85 | 13.30 | 0.1x the median |
Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 20, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B